[go: up one dir, main page]

AR125250A1 - Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas - Google Patents

Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas

Info

Publication number
AR125250A1
AR125250A1 ARP220100771A ARP220100771A AR125250A1 AR 125250 A1 AR125250 A1 AR 125250A1 AR P220100771 A ARP220100771 A AR P220100771A AR P220100771 A ARP220100771 A AR P220100771A AR 125250 A1 AR125250 A1 AR 125250A1
Authority
AR
Argentina
Prior art keywords
psilocybin
procedures
compositions
composition
manufacture
Prior art date
Application number
ARP220100771A
Other languages
English (en)
Inventor
David Philip Elder
Nigel Richardson
Original Assignee
Compass Pathfinder Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compass Pathfinder Ltd filed Critical Compass Pathfinder Ltd
Publication of AR125250A1 publication Critical patent/AR125250A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente divulgación proporciona composiciones farmacéuticas estables y sólidas que comprenden una cantidad terapéuticamente eficaz de psilocibina y uno o más excipientes farmacéuticamente aceptables. También se desvelan procedimientos de fabricación de dichas composiciones y uso de las mismas en el tratamiento de trastornos depresivos. Reivindicación 1: Una composición farmacéutica sólida y estable que comprende: una cantidad terapéuticamente eficaz de psilocibina; y uno o más excipientes farmacéuticamente aceptables, en la que, después del almacenamiento de la composición a 40ºC y el 75% de humedad relativa durante un mes, la potencia de la psilocibina en la composición disminuye en menos del 5% y el balance másico de la psilocibina y las sustancias relacionadas es superior al 97%.
ARP220100771A 2021-03-30 2022-03-30 Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas AR125250A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163168055P 2021-03-30 2021-03-30

Publications (1)

Publication Number Publication Date
AR125250A1 true AR125250A1 (es) 2023-06-28

Family

ID=81448508

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP220100771A AR125250A1 (es) 2021-03-30 2022-03-30 Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas
ARP220101430A AR126005A1 (es) 2021-03-30 2022-05-31 Composiciones de psilocibina, métodos de fabricación y métodos de uso de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP220101430A AR126005A1 (es) 2021-03-30 2022-05-31 Composiciones de psilocibina, métodos de fabricación y métodos de uso de las mismas

Country Status (15)

Country Link
US (1) US20240197758A1 (es)
EP (1) EP4312995A1 (es)
JP (1) JP2024512983A (es)
KR (1) KR20230175186A (es)
CN (1) CN117460498A (es)
AR (2) AR125250A1 (es)
AU (1) AU2022246987A1 (es)
BR (1) BR112023018472A2 (es)
CA (1) CA3210649A1 (es)
CO (1) CO2023013050A2 (es)
IL (1) IL305435A (es)
MX (1) MX2023011326A (es)
PH (1) PH12023552741A1 (es)
TW (1) TW202304466A (es)
WO (1) WO2022207746A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CN113993522A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法
EP4155306A1 (en) 2021-01-15 2023-03-29 Beckley Psytech Limited Neuroactive ergoline analogue
JP2025500844A (ja) 2021-12-13 2025-01-15 コンパス パスファインダー リミテッド 治療抵抗性うつ病の治療に使用するためのサイロシビン及び補助的セロトニン再取り込み阻害剤
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2391030T3 (es) 2005-03-23 2012-11-20 Bpsi Holdings, Llc. Composiciones de almidón aglomerado
US20210069170A1 (en) * 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
GB2571696B (en) * 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CA3127854A1 (en) * 2019-01-30 2020-08-06 Judith BLUMSTOCK Methods and compositions comprising a 5ht receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders
CN113993522A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US11766445B2 (en) * 2019-07-18 2023-09-26 Concept Matrix Solutions Oral soft gel capsule containing psychedelic compound
MX2024005632A (es) * 2021-11-09 2024-07-29 Compass Pathfinder Ltd Tratamiento de la depresion resistente al tratamiento con psilocibina.
JP2025500844A (ja) * 2021-12-13 2025-01-15 コンパス パスファインダー リミテッド 治療抵抗性うつ病の治療に使用するためのサイロシビン及び補助的セロトニン再取り込み阻害剤

Also Published As

Publication number Publication date
IL305435A (en) 2023-10-01
CO2023013050A2 (es) 2023-10-19
KR20230175186A (ko) 2023-12-29
PH12023552741A1 (en) 2024-03-04
US20240197758A1 (en) 2024-06-20
AU2022246987A1 (en) 2023-09-07
CN117460498A (zh) 2024-01-26
EP4312995A1 (en) 2024-02-07
WO2022207746A1 (en) 2022-10-06
BR112023018472A2 (pt) 2023-10-10
TW202304466A (zh) 2023-02-01
AR126005A1 (es) 2023-08-30
MX2023011326A (es) 2023-10-03
CA3210649A1 (en) 2022-10-06
JP2024512983A (ja) 2024-03-21

Similar Documents

Publication Publication Date Title
AR125250A1 (es) Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas
BR112023020442A2 (pt) Inibidor da protease 1 específica de ubiquitina (usp1)
PH12021553107A1 (en) Benzisoxazole sulfonamide derivatives
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
HUP0302474A2 (hu) Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR040434A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
PH12021551232A1 (en) Haloallylamine compounds and application thereof
BR112022001567A2 (pt) Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias.
PE20250018A1 (es) Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
ZA202306956B (en) Long acting injectable compositions of cariprazine or its pharmaceutically acceptable salts
MX2020012377A (es) Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
JOP20220093A1 (ar) تركيبة صيدلانية تشتمل على سيليكسيباغ
PH12021550218A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
WO2021070200A3 (en) Stable compositions of (7as,2's)-2-oxoclopidogrel and its pharmaceutical salts
BR112023015272A2 (pt) Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas
CL2023002871A1 (es) Composiciones nasales que comprenden alcaftadina
CL2022000118A1 (es) Formulaciones orales de edaravone y método de fabricación de las mismas.
MX2022015524A (es) Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.
MX2022001429A (es) Formulaciones que incluyen dihidrohonokiol.
AR052062A1 (es) Composicion y metodo para tratar el asma
AR124178A1 (es) Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación
PH12022551126A1 (en) Orally disintegrating pharmaceutical compositions of apixaban
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables